Journal of Nanomedicine & Nanotechnology

Nanotechnology based oral drug delivery - Where do we stand?

8^th World Medical Nanotechnology Congress & Expo

June 08-09, 2016 Dallas, USA

Samir Malhotra

Postgraduate Institute of Medical Education and Research, India

Posters & Accepted Abstracts: J Nanomed Nanotechnol

Abstract:

Nanotechnology is being used to improve drug therapy for reducing the toxicity of drugs or for providing a sustained release drug delivery. Several formulations are currently available that use nanotechnology for delivery of drugs; for example, paclitaxel for intravenous administration and dexamethasone for intravitreous use. Our work has focused on orally administered nanoformulations in two main areas �?? infectious disorders and cardiovascular disease. The work on an oral nanoformulation of firstline antitubercular drugs has now reached a stage when we will be initiating a phase 1 clinical trial. The work on second line antitubercular drugs has shown promise with respect to pharmacokinetics and toxicity profile. Our work on ischemic heart disease and hypertension can potentially allow us to reduce the pill burden and we are currently evaluating the pharmacodynamics of a �??nanopolypill�?� as the pharmacokinetics of this polypill showed a sustained release much beyond the conventional administration in rats. In order to bring such nanoformulations to the clinic, our lab conducts the toxicity studies required by the regulatory agencies, including single-dose acute and repeat-dose toxicity studies, genotoxicity evaluation, etc. We are looking for more partners, both in academia and industry; interested in helping us scale-up the nanoformulation production and conduct reproducibility studies of our lab technology when the formulation is manufactured on a large scale.

Biography :

Email: smal.pgi@gmail.com